Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06417814 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
744
Enrollment target
20
Study locations

NCT06417814 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 744 participants, above the 369-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (102% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06417814, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
744 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Conditions Studied

Metastatic Non Small Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Osimertinib
  • DRUG Pemetrexed
  • DRUG Dato-DXd

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Fountain Valley
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - San Diego

Massachusetts

  • Research Site - Boston
  • Research Site - Boston
  • Research Site - Boston

Colorado

  • Research Site - Colorado Springs
  • Research Site - Fort Collins

Florida

  • Research Site - Gainesville
  • Research Site - Jacksonville

Illinois

  • Research Site - Chicago
  • Research Site - Evanston

Maryland

  • Research Site - Baltimore
  • Research Site - Bethesda

Arkansas

  • Research Site - Fayetteville

Georgia

  • Research Site - Athens

Trial Details

FieldValue
Enrollment Target 744 participants
Start Date 2024-10-04
Est. Completion 2028-09-27
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06417814

The ClinicalTrials.gov registry entry for NCT06417814 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 369-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (102% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT06417814 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Massachusetts, Colorado.

Frequently Asked Questions

What is clinical trial NCT06417814 about?

NCT06417814 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer". This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

What is the current status of trial NCT06417814?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2024-10-04. Estimated completion is 2028-09-27.

What conditions does trial NCT06417814 study?

This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT06417814?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG), Dato-DXd (DRUG).

Who is sponsoring clinical trial NCT06417814?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06417814 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Non Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Non Small Cell Lung Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.